Attal Nadine, Barrot Michel
CETD, Ambroise Pare Hospital, APHP, Boulogne-Billancourt, France; Inserm U987, UVSQ-Paris-Saclay University, Ambroise Pare Hospital, APHP, Boulogne-Billancourt, France.
Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique and Université de Strasbourg, Strasbourg, France.
Br J Anaesth. 2025 Aug 11. doi: 10.1016/j.bja.2025.07.043.
The opioid crisis has prompted an urgent search for nonopioid analgesics for both acute and chronic pain. Among these, sodium channel antagonists, particularly those targeting Na1.7 and Na1.8, have emerged as potential pain management solutions. Recent large trials have shown some efficacy of the new Na1.8 allosteric inhibitor suzetrigine in acute postoperative pain, and ongoing studies are investigating its potential for painful diabetic neuropathy. If efficacy is confirmed, this type of drug might fill a significant gap in the treatment of acute and chronic pain, offering a safer alternative to opioids and marking the advent of a new class of nonopioid analgesics.
阿片类药物危机促使人们迫切寻找用于急性和慢性疼痛的非阿片类镇痛药。其中，钠通道拮抗剂，特别是那些靶向Na1.7和Na1.8的拮抗剂，已成为潜在的疼痛管理解决方案。最近的大型试验表明，新型Na1.8变构抑制剂舒泽曲秦在急性术后疼痛中有一定疗效，正在进行的研究正在调查其对糖尿病性疼痛性神经病变的治疗潜力。如果疗效得到证实，这类药物可能会填补急性和慢性疼痛治疗中的一个重大空白，提供一种比阿片类药物更安全的选择，并标志着一类新型非阿片类镇痛药的出现。
